drugset / Trial / NCT04849728
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Timeline
- Start
- 2021-08-19
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanifibranor | Small molecule | 800 mg | — |
| Subject | Lanifibranor | Small molecule | 1200 mg | — |